A Phase 2 interventional study of DAOIB in Dementia, sponsored by Chang Gung Memorial Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Dementia by Chang Gung Memorial Hospital — 9 open to participants now, 10 under way, none of them phase 3. Dementia · Chang Gung Memorial Hospital.
Among the 23 studies in Dementia by Chang Gung Memorial Hospital, this one is the 9th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 2, and was the 16th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →9 of the 23 studies in Dementia by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 40+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 55+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 50–100
Chang Gung Memorial Hospital
Ages 20+ · Healthy volunteers
By country, each count listing its studies:
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8
First in 2009; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 123 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 97 across the 21 interventional studies, 175 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
3 of the studies in Dementia by Chang Gung Memorial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07458620Chang Gung Memorial HospitalProspective Single-Arm Safety Study of Cervical LVA in AD Patients | 2027-05 |
| NCT07823634Chang Gung Memorial HospitalDevelopment and Preliminary Application Evaluation of a Clinical Decision Support Training Platform for Dementia Care | 2027-06 |
| NCT07033468Chang Gung Memorial HospitalThe Feasibility and the Efficacy of the Full-immersive Virtual Reality Cognitive Training in Patients With Mild or Moderate Dementia | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Dementia by Chang Gung Memorial Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)
Time frame: week 0, 8, 16, 24
Change from baseline in the composite score of a battery of additional cognitive tests at week 24
The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (Wechsler Memory Scale, Spatial Span), verbal/nonverbal learning and memory tests (Wechsler Memory Scale, Word Listing)
Time frame: week 0, 24
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Time frame: week 8, 16, 24
Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24
The assessment appears to be a suitable instrument for evaluating activities of daily living in early-phase dementia. Its scores range from 0 (worst) to 78 (best)
Time frame: week 0, 8, 16, 24
Change from baseline of Geriatric Depression Scale
Assessment of geriatric depressive symptoms
Time frame: week 0, 8, 16, 24
Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24
Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24
Time frame: week 0, 8, 16, 24
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Sep 2026, 47 months after the start.
Of 43 non-industry phase 2 interventional studies under Dementia, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 78. This study's planned 47 months is below that.
Counting every sponsor, half of 84 studies reached it within 38 months; a quarter within 23 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Benzoate
Chang Gung Memorial Hospital →